Page 189 - NobleCon20-Book-Project

Zomedica Corp.

SELECTED FINANCIAL ITEMS ZOM

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue 7.34 6.26 6.13 7.00 26.73
Gross Profit 5.07 4.12 4.36 5.06 18.61
Gross Margin 69% 66% 71% 72% 70%
EBIT (11.39) (10.39) (9.04) (7.44) (38.26)
EBIT Margin -155% -166% -147% -106% -143%
Net Income to Common Shareholders (22.41) (9.16) (23.93) (6.70) (62.19)
Net Margin -305% -146% -390% -96% -233%

Balance Sheet Key Items
Total Assets 253.20 243.70 219.88 214.12 214.12
Cash & Short Term Investments 12.95 10.94 7.94 9.75 9.75
% of Assets 5% 4% 4% 5% 5%
Current Assets -Total 99.88 92.07 89.22 87.27 87.27
% of Assets 39% 38% 41% 41% 41%
Total Liabilities 13.18 11.81 11.16 11.27 11.27
% of Assets 5% 5% 5% 5% 5%
Current Liabilities - Total 9.03 8.01 7.84 8.06 8.06
% of Assets 4% 3% 4% 4% 4%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 240.02 231.90 208.72 202.84 202.84
% of Assets 95% 95% 95% 95% 95%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (5.02) (7.59) (6.72) (4.80) (24.12)
Net Cash Flow - Investing (3.83) 5.63 3.77 6.54 12.11
Net Cash Flow - Financing NA NA NA (0.07) (0.07)

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference